Sara Gharehdaghi
Research Subjects
Sara Gharehdaghi has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Jerrold Spapen
Cardiovascular Center Aalst, AZORG Hospital, Aalst, Belgium
2 shared publicationsLiesbeth Rosseel
Cardiovascular Center Aalst, AZORG Hospital, Aalst, Belgium
2 shared publicationsMarc Vanderheyden
Cardiovascular Center Aalst, AZORG Hospital, Aalst, Belgium
2 shared publicationsMartin Penicka
Cardiovascular Center Aalst, AZORG Hospital, Aalst, Belgium
2 shared publicationsMonika Beles
Cardiovascular Center Aalst, AZORG Hospital, Aalst, Belgium
2 shared publications- Annamária Kosztin
Semmelweis University Heart and Vascular Center, Budapest, Hungary
1 shared publication
Latest Publications
- Open Access
- 9 July 2026
- Published by BMJ in Open Heart
- Vol. 13 (2) , e003981
Integrating RV–PA coupling and geometry-based indices into the TRI-SCORE improves prognostic assessment in tricuspid regurgitation
Background: Tricuspid regurgitation (TR) is a progressive and underdiagnosed condition associated with poor prognosis. Although the TRI-SCORE is a validated risk model for patients undergoing tricuspid valve surgery, it does not incorporate echocardiographic measures of right ventricular (RV) function or RV–pulmonary artery coupling, which are increasingly recognised as major prognostic determinants. Objectives: To evaluate whether integration of simple, widely available echocardiographic indices—tricuspid annular plane systolic excursion (TAPSE)/pulmonary artery systolic pressure (PASP), TAPSE/RV end-diastolic area (RVAD) and TAPSE/RV end-systolic area (RVAS)—improves the prognostic performance of the TRI-SCORE in patients with moderate-to-severe TR. Methods: We retrospectively included 93 patients with severe TR, including functional, mixed and primary/Cardiac Implantable Electronic Device (CIED)-related aetiologies treated with medical therapy, surgery or transcatheter edge-to-edge repair. The primary endpoint was all-cause mortality; the secondary endpoint was a composite of mortality or heart failure hospitalisation. Multivariable Cox regression models were used to assess the incremental predictive value of each TAPSE-derived ratio beyond the TRI-SCORE. Optimal thresholds were derived using spline regression and maximally selected rank statistics. Results: Lower TAPSE/PASP, TAPSE/RVAD and TAPSE/RVAS values were independently associated with worse outcomes. Each parameter significantly enhanced risk discrimination when added to the TRI-SCORE (C-index improved from 0.614 to 0.710 for TAPSE/PASP, 0.685 for TAPSE/RVAD and 0.696 for TAPSE/RVAS; all p<0.001). Prognostically relevant cut-offs were identified at 0.44, 0.80 and 1.3, respectively. Conclusions: Simple echocardiographic indices of RV function provide substantial incremental prognostic value when combined with the TRI-SCORE and may improve risk stratification and timing of intervention in isolated TR.
- 9 July 2026
- Published by BMJ in Open Heart
- Vol. 13 (2) , e003981
Open AccessIntegrating RV–PA coupling and geometry-based indices into the TRI-SCORE improves prognostic assessment in tricuspid regurgitation
Background: Tricuspid regurgitation (TR) is a progressive and underdiagnosed condition associated with poor prognosis. Although the TRI-SCORE is a validated risk model for patients undergoing tricuspid valve surgery, it does not incorporate echocardiographic measures of right ventricular (RV) function or RV–pulmonary artery coupling, which are increasingly recognised as major prognostic determinants. Objectives: To evaluate whether integration of simple, widely available echocardiographic indices—tricuspid annular plane systolic excursion (TAPSE)/pulmonary artery systolic pressure (PASP), TAPSE/RV end-diastolic area (RVAD) and TAPSE/RV end-systolic area (RVAS)—improves the prognostic performance of the TRI-SCORE in patients with moderate-to-severe TR. Methods: We retrospectively included 93 patients with severe TR, including functional, mixed and primary/Cardiac Implantable Electronic Device (CIED)-related aetiologies treated with medical therapy, surgery or transcatheter edge-to-edge repair. The primary endpoint was all-cause mortality; the secondary endpoint was a composite of mortality or heart failure hospitalisation. Multivariable Cox regression models were used to assess the incremental predictive value of each TAPSE-derived ratio beyond the TRI-SCORE. Optimal thresholds were derived using spline regression and maximally selected rank statistics. Results: Lower TAPSE/PASP, TAPSE/RVAD and TAPSE/RVAS values were independently associated with worse outcomes. Each parameter significantly enhanced risk discrimination when added to the TRI-SCORE (C-index improved from 0.614 to 0.710 for TAPSE/PASP, 0.685 for TAPSE/RVAD and 0.696 for TAPSE/RVAS; all p<0.001). Prognostically relevant cut-offs were identified at 0.44, 0.80 and 1.3, respectively. Conclusions: Simple echocardiographic indices of RV function provide substantial incremental prognostic value when combined with the TRI-SCORE and may improve risk stratification and timing of intervention in isolated TR.
- Open Access
- 9 April 2026
- Published by Elsevier in SSRN Electronic Journal
Prognostic value of the Tri-Score across treatment strategies in isolated tricuspid regurgitation - A Multicenter Retrospective Analysis
BackgroundThe Tri-Score is a surgical risk model developed to predict outcomes after isolated tricuspid valve surgery. Its prognostic value across contemporary treatment strategies, including transcatheter interventions and medical therapy, remains uncertain.MethodsIn this retrospective multicenter cohort study, 104 patients treated between 2010 and 2024 for isolated ≥moderate tricuspid regurgitation (TR) were included. Patients were managed with medical therapy (n=31), surgery (n=40), or transcatheter edge-to-edge repair (T-TEER; n=33). The primary endpoint was all-cause mortality during follow-up, and the secondary endpoint was a composite of all-cause mortality or heart failure hospitalization. Outcomes were analyzed according to baseline Tri-Score categories: low (0–3), intermediate (4–5), and high (≥6). Multivariable Cox regression adjusted for treatment strategy, age, and sex.ResultsMean age was 74.8±12.9 years, and 62% were female. Median follow-up was 45 months (IQR 27–63). TR reduction to <moderate at one year occurred in 39% of medically treated patients, 92% of surgical patients, and 70% of T-TEER patients. One-year mortality increased across Tri-Score categories (6%, 13%, and 33% for low, intermediate, and high risk; log-rank p<0.001). The Tri-Score independently predicted mortality (HR 1.23 per point; 95% CI 1.08–1.40) and the composite endpoint (HR 1.34 per point; 95% CI 1.17–1.52).ConclusionsThe Tri-Score is an independent predictor of adverse outcomes in isolated ≥moderate TR, irrespective of treatment modality. As such, it supports early risk stratification and may help guide the timing of therapeutic interventions. Early intervention at low Tri-Scores results in excellent outcomes, whereas high-risk patients warrant tailored, multidisciplinary evaluation.
- 9 April 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessPrognostic value of the Tri-Score across treatment strategies in isolated tricuspid regurgitation - A Multicenter Retrospective Analysis
BackgroundThe Tri-Score is a surgical risk model developed to predict outcomes after isolated tricuspid valve surgery. Its prognostic value across contemporary treatment strategies, including transcatheter interventions and medical therapy, remains uncertain.MethodsIn this retrospective multicenter cohort study, 104 patients treated between 2010 and 2024 for isolated ≥moderate tricuspid regurgitation (TR) were included. Patients were managed with medical therapy (n=31), surgery (n=40), or transcatheter edge-to-edge repair (T-TEER; n=33). The primary endpoint was all-cause mortality during follow-up, and the secondary endpoint was a composite of all-cause mortality or heart failure hospitalization. Outcomes were analyzed according to baseline Tri-Score categories: low (0–3), intermediate (4–5), and high (≥6). Multivariable Cox regression adjusted for treatment strategy, age, and sex.ResultsMean age was 74.8±12.9 years, and 62% were female. Median follow-up was 45 months (IQR 27–63). TR reduction to <moderate at one year occurred in 39% of medically treated patients, 92% of surgical patients, and 70% of T-TEER patients. One-year mortality increased across Tri-Score categories (6%, 13%, and 33% for low, intermediate, and high risk; log-rank p<0.001). The Tri-Score independently predicted mortality (HR 1.23 per point; 95% CI 1.08–1.40) and the composite endpoint (HR 1.34 per point; 95% CI 1.17–1.52).ConclusionsThe Tri-Score is an independent predictor of adverse outcomes in isolated ≥moderate TR, irrespective of treatment modality. As such, it supports early risk stratification and may help guide the timing of therapeutic interventions. Early intervention at low Tri-Scores results in excellent outcomes, whereas high-risk patients warrant tailored, multidisciplinary evaluation.
- Open Access
- 28 September 2023
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 25 (10)
Time-trend treatment effect of cardiac resynchronization therapy with or without defibrillator on mortality: a systematic review and meta-analysis
This study aimed to investigate the impact of cardiac resynchronization therapy with a defibrillator (CRT-D) on mortality, comparing it with CRT with a pacemaker (CRT-P). Additionally, the study sought to identify subgroups, evaluate the time trend in treatment effects, and analyze patient characteristics, considering the changing indications over the past decades. PubMed, CENTRAL, and Embase up to October 2021 were screened for studies comparing CRT-P and CRT-D, focusing on mortality. Altogether 26 observational studies were selected comprising 128 030 CRT patients, including 55 469 with CRT-P and 72 561 with CRT-D device. Cardiac resynchronization therapy with defibrillator was able to reduce all-cause mortality by almost 20% over CRT-P [adjusted hazard ratio (HR): 0.85; 95% confidence interval (CI): 0.76–0.94; P < 0.01] even in propensity-matched studies (HR: 0.83; 95% CI: 0.80–0.87; P < 0.001) but not in those with non-ischaemic aetiology (HR: 0.95; 95% CI: 0.79–1.15; P = 0.19) or over 75 years (HR: 1.08; 95% CI 0.96–1.21; P = 0.17). When treatment effect on mortality was investigated by the median year of inclusion, there was a difference between studies released before 2015 and those thereafter. Time-trend effects could be also observed in patients’ characteristics: CRT-P candidates were getting older and the prevalence of ischaemic aetiology was increasing over time. The results of this systematic review of observational studies, mostly retrospective with meta-analysis, suggest that patients with CRT-D had a lower risk of mortality compared with CRT-P. However, subgroups could be identified, where CRT-D was not superior such as non-ischaemic and older patients. An improved treatment effect of CRT-D on mortality could be observed between the early and late studies partly related to the changed characteristics of CRT candidates.
- 28 September 2023
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 25 (10)
Open AccessTime-trend treatment effect of cardiac resynchronization therapy with or without defibrillator on mortality: a systematic review and meta-analysis
This study aimed to investigate the impact of cardiac resynchronization therapy with a defibrillator (CRT-D) on mortality, comparing it with CRT with a pacemaker (CRT-P). Additionally, the study sought to identify subgroups, evaluate the time trend in treatment effects, and analyze patient characteristics, considering the changing indications over the past decades. PubMed, CENTRAL, and Embase up to October 2021 were screened for studies comparing CRT-P and CRT-D, focusing on mortality. Altogether 26 observational studies were selected comprising 128 030 CRT patients, including 55 469 with CRT-P and 72 561 with CRT-D device. Cardiac resynchronization therapy with defibrillator was able to reduce all-cause mortality by almost 20% over CRT-P [adjusted hazard ratio (HR): 0.85; 95% confidence interval (CI): 0.76–0.94; P < 0.01] even in propensity-matched studies (HR: 0.83; 95% CI: 0.80–0.87; P < 0.001) but not in those with non-ischaemic aetiology (HR: 0.95; 95% CI: 0.79–1.15; P = 0.19) or over 75 years (HR: 1.08; 95% CI 0.96–1.21; P = 0.17). When treatment effect on mortality was investigated by the median year of inclusion, there was a difference between studies released before 2015 and those thereafter. Time-trend effects could be also observed in patients’ characteristics: CRT-P candidates were getting older and the prevalence of ischaemic aetiology was increasing over time. The results of this systematic review of observational studies, mostly retrospective with meta-analysis, suggest that patients with CRT-D had a lower risk of mortality compared with CRT-P. However, subgroups could be identified, where CRT-D was not superior such as non-ischaemic and older patients. An improved treatment effect of CRT-D on mortality could be observed between the early and late studies partly related to the changed characteristics of CRT candidates.